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Alternative splice variants of fibroblast growth factor recep-
tor 2 (FGFR2) IIIb, designated C1, C2, and C3, possess progres-
sive reduction in their cytoplasmic carboxyl termini (822, 788,
and 769 residues, respectively), with preferential expression of
the C2 and C3 isoforms in human cancers. We determined that
the progressive deletion of carboxyl-terminal sequences corre-
lated with increasing transforming potency. The highly trans-
forming C3 variant lacks five tyrosine residues present in C1,
and we determined that the loss of Tyr-770 alone enhanced
FGFR2 IIIb C1 transforming activity. Because Tyr-770 may
compose a putative YXXL sorting motif, we hypothesized that
loss of Tyr-770 in the 770YXXL motif may cause disruption of
FGFR2 IIIb C1 internalization and enhance transforming activ-
ity. Surprisingly, we found that mutation of Leu-773 but not
Tyr-770 impaired receptor internalization and increased recep-
tor stability and activation. Interestingly, concurrent mutations
of Tyr-770 and Leu-773 caused 2-fold higher transforming
activity than caused by the Y770F or L773A single mutations,
suggesting loss of Tyr and Leu residues of the 770YXXL773 motif
enhances FGFR2 IIIb transforming activity by distinct mecha-
nisms. We also determined that loss of Tyr-770 caused persis-
tent activation of FRS2 by enhancing FRS2 binding to FGFR2
IIIb. Furthermore, we found that FRS2 binding to FGFR2 IIIb is
required for increased FRS2 tyrosine phosphorylation and
enhanced transforming activity by Y770F mutation. Our data
support a dual mechanism where deletion of the 770YXXL773
motif promotes FGFR2 IIIb C3 transforming activity by causing
aberrant receptor recycling and stability and persistent FRS2-
dependent signaling.
Fibroblast growth factors (FGFs)2 compose a large family of
structurally related growth factors (22 human members) that
mediate cell proliferation, differentiation, migration, and
angiogenesis (1–4). The activities of FGFs are mediated by
their binding to a family of four receptor tyrosine kinases
(RTKs), designated FGFR1–4 (5). FGFRs are composed of an
extracellular domain that consists of two or three Ig-like
domains, a single transmembrane domain, and an intracel-
lular catalytic tyrosine kinase domain and flanking regula-
tory sequences (Fig. 1A).
An important feature andmode of regulation of FGFR2 func-
tion is that structural variants of FGFR2 are generated by
numerous alternative gene splicing events that generate tran-
scripts that encode proteins altered in both the extracellular
and intracellular regions of the FGFR2 (5). To date, more than
20 alternative splicing variants of FGFR2 have been identified.
The first major splicing event occurs in the second half of the
third Ig-like domain (designated Ig-III domain). Tissue-specific
inclusion of either exon IIIb or exon IIIc that encodes for the
second half of the Ig-III domain generates either the epithelial
cell-specific IIIb or mesenchymal cell-specific IIIc isoforms (6).
This alternative splicing determines the ligand binding speci-
ficity of FGFR2. Although FGFR2 IIIb (also called KGFR) binds
FGF7 (also called KGF) and FGF10, but not FGF2, FGFR2 IIIc
(also called BEK) binds FGF2, but not FGF7 and FGF10 (7–10).
Interestingly, although FGFR2 IIIb expression is restricted to
epithelial cells (6), expression of the ligands for FGFR2 IIIb
(FGF7 and FGF10) is restricted to mesenchymal cells (11–16),
resulting in the creation of a paracrine signaling loop in epithe-
lial-mesenchymal interactions that is likely to be critically for
promoting FGFR2 IIIb activity in oncogenesis.
The second major splicing occurs in sequences that encode
the carboxyl terminus of FGFR2. Three splice variants of
FGFR2 IIIb that differ in their carboxyl-terminal sequences
have been identified (designated C1, C2, and C3) (17). The
C2-type carboxyl terminus is 34 amino acids shorter than the
C1-type carboxyl terminus, and the C3-type carboxyl terminus
is 19 amino acids shorter than C2-type carboxyl terminus (Fig.
1A). These sequence differences result in differential retention of
tyrosine residues thatmay serve as sites of receptor autophospho-
rylation and docking sites for cytoplasmic signaling proteins.
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Aprevious study found that expression of theC3 isoformwas
increased in gastric cancer cell lines (17). We also observed
enhanced expression of C2 and C3 isoforms in a majority of
human breast carcinoma cell lines when compared with non-
transformed MCF-10A human mammary epithelial cells (18),
suggesting that aberrant expression of the C2 or C3 splicing vari-
ants may contribute to cancer development. Furthermore, the C3
variant that lacks carboxyl-terminal sequences was shown to be
more transforming than the IIIb C1 variant when expressed
ectopically in NIH 3T3 fibroblasts and human mammary epithe-
lial cells (17, 19).However,whether theC2variant ismore (or less)
transforming than theC1 (orC3)varianthasnotbeendetermined.
Furthermore, the mechanistic basis for the enhanced transform-
ing activity of the C3 variant remains to be elucidated.
Like other RTKs, FGFRs are activated by ligand-induced
dimerization, causing stimulation of their intrinsic tyrosine
kinase activity, tyrosine autophosphorylation, and recruitment
of signaling proteins to specific phosphorylated tyrosine resi-
dues in their cytoplasmic carboxyl termini. The two best char-
acterized downstream signaling components of FGFRs are
phospholipaseC- (PLC) andFGF receptor substrate 2 (FRS2)
(1–4). In FGFR1, Tyr-766 in the carboxyl terminus is themajor
autophosphorylation site on FGFR1 and serves as a binding site
for the Src homology 2 domain of PLC, resulting in tyrosine
phosphorylation and activation of PLC (20, 21), leading to
stimulation of phosphatidylinositol (PI) hydrolysis and the gen-
eration of diacylglycerol and inositol 1,4,5-trisphosphate (22).
The Tyr-766 residue in FGFR1 is well conserved in all four
FGFR family members and corresponds to Tyr-770 in FGFR2
IIIb (Fig. 1B). Recently, it was shown that a Y770F missense
mutant of FGFR2 IIIb C1 cannot bind and phosphorylate PLC
(23). However, whether this mutant fails to activate PI hydrol-
ysis and whether altered PLC binding and activation contrib-
ute to FGFR2 transforming activity remain unresolved.
Unlike PLC, FRS2 associationwith FGFR is constitutive and
independent of ligand stimulation and receptor phosphoryla-
tion (24). FRS2 is a docking protein that binds to a conserved
sequencewithin the juxtamembrane domain of FGFRs. Ligand-
stimulated activation of FGFRs leads to phosphorylation of
multiple tyrosine residues in FRS2 (25). One well characterized
FRS2 effector is the Grb2 adaptor protein that binds to tyro-
sine-phosphorylated FRS2 and forms a stable complex with the
Sos Ras guanine nucleotide exchange factor, thus stimulating
activation of the Ras small GTPase and the ERKMAPK cascade
(25). In addition, Grb2 can recruit the docking protein Gab1,
which is then tyrosine-phosphorylated by FGFR2 activation.
The tyrosine-phosphorylated Gab1 recruits phosphatidylinosi-
tol 3-kinase (PI3K), resulting in activation of the AKT serine/
threonine kinase (26).
One mechanism of negative regulation of RTK signaling
involves ligand-mediated receptor internalization and lysosomal
degradation (27, 28).Therefore,disruptionof receptor internaliza-
tion could lead to aberrant receptor activation and contribute to
the development of human disease, including cancer. Interest-
ingly, FGFR2 IIIb C1 contains a putative YXX tyrosine-based
sorting motif (where X is any amino acid and  is a bulky hydro-
phobic amino acid) (29) in carboxyl-terminal sequences deleted in
the C3 variant, suggesting that the loss of the YXX motif might
impair receptor internalization and contribute to the enhanced
transforming activity of the FGFR2 IIIb C3 variant.
To date, a detailed comparative analysis of the transform-
ing potential of FGFR2 IIIb C1, C2, and C3 using the same
cell system has not been done. In this study, we compared the
transforming potency of FGFR2 IIIb C1, C2, and C3 splicing
variants and found that the C3 variant is considerably more
transforming than the C2 variant, and the C2 variant is mod-
estly enhanced in transforming activity when compared with
the weakly transforming C1 variant. Our results support a
model where the potent transforming activity of the FGFR2
IIIb C3 splice variant is mediated, in part, by a mechanism
involving loss of the 770YLDL motif, resulting in impaired
receptor internalization and enhanced FRS2-dependent
signaling.
EXPERIMENTAL PROCEDURES
Plasmid Expression Vectors—Human FGFR2 IIIb C1, C2,
and C3 cDNA sequences were generated by PCR amplifica-
tion from a T-47D breast cancer cell cDNA library and sub-
cloned into the pBabe-puro retrovirus mammalian expres-
sion vector (5-SalI and 3-BamHI sites). The FGFR2 IIIb C2
(QST) cDNA sequence (deletion of FGFR2 IIIb C1 residues
789–822) was created by PCR amplification from the FGFR2
IIIb C1 cDNA sequence and subcloned into pBabe-puro (5-
SalI and 3-BamHI sites). Additional cDNA sequences
encoding missense mutations were created by site-directed
mutagenesis using the QuikChange site-directed mutagene-
sis kit (Stratagene) and verified by DNA sequencing. Oligo-
nucleotides designed to create the appropriate mutations to













Cell Culture and Transformation Assay—Rat-1 and RIE-1
cells were maintained in Dulbecco’s modified minimum essen-
tial medium supplemented with 10% fetal calf serum. For sec-
ondary focus formation assays, Rat-1 and RIE-1 cells were sta-
bly infected with pBabe-puro constructs encoding wild type
FGFR2 IIIb isoforms and missense mutants of FGFR2 IIIb C1.
Expression of ectopically introduced FGFR2 IIIb C1 proteins
was determined by immunoblot analyseswith anti-FGFR2 anti-
body (sc-122; Santa Cruz Biotechnology). After infection, cells
were selected in growth medium supplemented with puromy-
cin (2g/ml). Drug-resistant colonieswere pooled and replated
into 60-mm dishes and maintained in growth medium for 2–3
weeks. Cells were then fixed and stained with crystal violet. To
determine anchorage-independent growth potential, Rat-1
cells stably expressing either the pBabe-puro empty vector or
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encoding various FGFR2 IIIb proteins were suspended in 0.4%
bacto-agar in growth medium at 5  104 cells per 60-mm dish.
After 2–3 weeks, colonies were stained with 2 mg/ml 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, and the
average number of colonies on duplicate dishes was calculated.
For conditioned medium assays, Rat-1 fibroblast conditioned
medium was collected and passaged through a 0.45-m filter.
RIE-1 cells stably infected with the pBabe-puro empty vector,
or encoding WT or Y770F mutant FGFR2 IIIb C1, were grown
either in conditioned medium or regular growth medium,
replenished every 2 days, for 3 weeks before cells were fixed and
stained with crystal violet.
Immunofluorescence Microscopy—Rat-1 cells that stably
express either wild type or mutant FGFR2 IIIb proteins were
serum-starved for 20 h and then incubated with either vehicle
(bovine serum albumin (BSA)) or 50 ng/ml FGF7 (R & D Sys-
tems) for 40 min at 37 °C to allow internalization. Cells were
then fixed using 4% paraformaldehyde in phosphate-buffered
saline (PBS), washed, and permeabilized (0.1% Triton X-100).
Next, cells were immunostained with rabbit polyclonal FGFR2
antibody (sc-122; Santa Cruz Biotechnology) to determine
FGFR2 IIIb subcellular location by Zeiss 510 LSM confocal
microscope.
Cleavable Biotin Internalization Assay—Internalization of
FGFR2 IIIb was quantitatively measured as described previ-
ously (30) with the followingmodifications. Rat-1 cells that sta-
bly express eitherwild type ormutant FGFR2 IIIb proteinswere
serum-starved for 20 h. The cells were then washed three times
with ice-cold PBS containing Ca2 and Mg2 (Ca2/Mg2
PBS). For surface biotinylation, cells were incubated with thiol-
cleavable sulfo-NHS-S-S-biotin (0.5 mg/ml; Pierce) for 1 h on
ice. Cells were then washed three times with ice-cold Ca2/
Mg2 PBS and stimulated with FGF7 at 37 °C for the indicated
times to allow internalization. Cells were then put back on ice
and washed three times with ice-cold Ca2/Mg2 PBS. To
remove the residual surface biotin, cells were washed three
times, for 15 min each, with ice-cold glutathione (GSH; mem-
brane-nonpermeable reducing agent) cleavage solution (50mM
glutathione, 75mMNaCl, 1mM EDTA, 1% BSA, and 0.75% 10 N
NaOH). Cells were further washed twice on ice with Ca2/
Mg2 PBS and incubated for 15 min with 5 mg/ml iodoacet-
amide (in Ca2/Mg2 PBS with 1% BSA; quenching buffer) to
quench free sulfo-reactive groups. Cells were then washed five
times, lysed, and immunoprecipitated with Neutravidin beads
(Pierce) followed by immunoblotting with FGFR2 antibody.
Immunoblot band intensity was quantified by ImageJ analysis
(National Institutes of Health).
Receptor Down-regulation Assays—Rat-1 cells that stably
express either wild type or mutant FGFR2 IIIb proteins were
incubated with 50 ng/ml FGF7 for the indicated times at 37 °C
to induce ligand-induced receptor degradation. Immunoblot-
ting analyses with FGFR2 antibody were performed to deter-
mine the level of remaining FGFR2 protein. Band intensity was
quantified by ImageJ analysis.
Signaling Analyses—To determine FGFR2 tyrosine auto-
phosphorylation, cells were lysed and analyzed for tyrosine-
phosphorylated FGFR2 by immunoprecipitation with an
anti-FGFR2 antibody followed by immunoblotting with an
anti-phosphotyrosine antibody (05-321, clone 4G10; Upstate
Biotechnology, Inc.). To determine PLC activation, cells were
lysed and then analyzed for tyrosine-phosphorylated PLC by
immunoprecipitation with anti-PLC antibody (sc-7290, clone
E-12; Santa Cruz Biotechnology) followed by immunoblotting
with anti-phosphotyrosine antibody. PI hydrolysis assays were
performed to measure PLC activity as we have described pre-
viously (31). Briefly, Rat-1 cells stably expressing either wild
type FGFR2 IIIb C1 or 770F mutant were labeled with myo-
[3H]inositol in inositol-free medium. Then cells were stimu-
lated with FGF7, vehicle (BSA, negative control), thrombin
(positive control), or lysophosphatidic acid (positive control)
for 20 min in medium supplemented with 10 mM LiCl. Accu-
mulation of [3H]inositol phosphates was quantitated as
described previously (31).
To determine FRS2 activation, cells were lysed and then ana-
lyzed for tyrosine-phosphorylated FRS2 by immunoprecipita-
tion with anti-FRS2 antibody (sc-8318; Santa Cruz Biotechnol-
ogy) followed by immunoblotting with anti-phosphotyrosine
antibody. To determine Gab1 activation, cells were lysed and
analyzed for tyrosine-phosphorylated Gab1 by immunopre-
cipitation with anti-Gab1 antibody (sc-9049; Santa Cruz Bio-
technology) followed by immunoblotting with anti-phosphoty-
rosine antibody. To determine MEK, ERK, or AKT activation,
cells were lysed and then analyzed for activeMEK, ERK, orAKT
by immunoblot analyses with antibody specifically to detect
phosphorylated MEK1/2 (9121; Cell Signaling Technology),
ERK (9106; Cell Signaling Technology), or AKT (9271; Cell
Signaling Technology). Total ERK and AKT levels were
determined by anti-ERK (9102; Cell Signaling Technology)
and anti-AKT antibodies (9272; Cell Signaling Technology),
respectively.
To determine FRS2 binding to FGFR2, cells were lysed and
immunoprecipitated with anti-FRS2 antibody followed by
immunoblotting with anti-FGFR2 antibody. The same mem-
brane was stripped and reprobed with the anti-FRS2 antibody
to determine the protein levels of endogenous FRS2.
RESULTS
Loss of Carboxyl-terminal Sequences Enhances FGFR2 IIIb
Transforming Potency in Rat-1 Fibroblasts and RIE-1 Epithelial
Cells—Todetermine the role of carboxyl-terminal sequences in
FGFR2 IIIb transformation, we compared the transforming
potency of FGFR2 IIIb C1, C2, and C3 variants by examining
two aspects of growth transformation, loss of density-depend-
ent growth inhibition, and acquisition of anchorage-indepen-
dent growth potential. For these analyses, we established Rat-1
rat fibroblasts and RIE-1 rat intestinal epithelial cells stably
expressing the FGFR2 IIIb C1, C2, or C3 variants. First, we
compared the ability of the three FGFR2 IIIb variants to induce
loss of density-dependent growth inhibition by quantitating the
appearance of foci of multilayered cells in confluent cultures.
Cells stably transfected with the empty vector or expressing the
C1 variant exhibited no focus forming activity. In contrast, we
found that cells expressing the C2 variant exhibited weak focus
forming activity, whereas the C3 variant caused significantly
greater focus forming activity than the C2 variant in RIE-1 (Fig.
1C) as well as Rat-1 cells (Fig. 1E).
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Second, we compared the ability
of three FGFR2 IIIb variants to
promote anchorage-independent
growth by soft agar assay. Consist-
ent with their relative focus-form-
ing potencies, the C3 variant
induced more soft agar colonies
than the C2 variant, and the C2 var-
iant inducedmore soft agar colonies
than the C1 variant in RIE-1 (Fig.
1D) as well as Rat-1 cells (Fig. 1F). A
similar hierarchy of transforming
potency, as measured by soft agar
colony formation, was seen when
the FGFR2 IIIb isoforms were stably
expressed in MCF-10 human breast
epithelial cells (data not shown).
These data indicate that multiple
carboxyl-terminal sequences func-
tion as negative regulators of FGFR2
IIIb transforming activity, with the
loss of residues within the region
spanning 769–788 causing themost
significant activation of transform-
ing activity.
Mutation of Y770F Alone Acti-
vates FGFR2 IIIb C1 Transforming
Activity in Rat-1 Fibroblasts—Next,
we determined the critical residue
losses that contribute to the
enhanced transforming activity of
FGFR2 IIIb variants lacking car-
boxyl-terminal sequences. The car-
boxyl-terminal domain tyrosine
residues of RTKs are sites of auto-
phosphorylation and critical for
their cytoplasmic signaling and
growth regulatory activities. The C3
variant lacks five tyrosine residues
(Tyr-770, Tyr-780, Tyr-784, Tyr-
806, and Tyr-813), whereas the C2
variant lacks two tyrosine residues
(Tyr-806 and Tyr-813) present in
the C1 isoform (Fig. 1A). We
hypothesized that the loss of spe-
cific tyrosine residue(s) might
account for the enhanced trans-
forming activity of the C2 and (or)
C3 variants. To address this possi-
bility, we introduced phenylalanine
substitutions at each of the five tyro-
sine residues (Y770F, Y780F, Y784F,
Y806F, and Y813F) of the carboxyl
terminus of the weakly transform-
ing C1 variant. Because loss of mul-
tiple tyrosine residues might be
required for enhanced transforming
activity, we also generated double
FIGURE 1. Loss of carboxyl-terminal sequences enhances FGFR2 IIIb transforming potency in RIE-1 epi-
thelial cells and Rat-1 fibroblasts. A, carboxyl-terminal sequence comparison of three FGFR2 IIIb splice vari-
ants (C1, C2, and C3). Known or putative phosphorylated tyrosine residues are indicated. B, conservation of
carboxyl-terminal tyrosines in FGFR family members. Of the five tyrosine residues present in the C1 but not C3
variant of FGFR2, only Tyr-770 (Tyr-766 in FGFR1) and Tyr-780 (Tyr-776 in FGFR1) are conserved in all four recep-
tors. Receptor autophosphorylation of Tyr-770 of FGFR2 IIIb (analogous to Tyr-766 of FGFR1 and Tyr-760 of FGFR3)
creates a recognition site for the Src homology 2 domain of PLC. C, loss of carboxyl-terminal sequences enhances
FGFR2 IIIb-induced focus formation in RIE-1 epithelial cells. Mass populations of RIE-1 cells that stably express the
indicated FGFR2 IIIb carboxyl-terminal splice variants were assayed for focus forming activity using a secondary
focus formation assay. Cells were plated and allowed to grow for 21 days, and then the appearance of foci of
transformed cells was monitored. The cultures were fixed and stained with crystal violet, and focus forming activity
was quantitated. D, loss of carboxyl-terminal sequences enhances FGFR2 IIIb-induced soft agar growth of RIE-1 cells.
Mass populations of RIE-1 cells that stably expressed the indicated FGFR2 IIIb variants were assayed for their ability
to grow in soft agar. The number of colonies was quantitated after 21 days. Data shown are the average of duplicate
dishes, with the bars indicating standard deviation, and are representative of three independent experiments. E, loss
of carboxyl-terminal sequences enhances FGFR2 IIIb-induced focus formation in Rat-1 cells. Analyses were done
similarly as described for RIE-1 cells. F, loss of carboxyl-terminal sequences enhances FGFR2 IIIb-induced soft agar
growth of Rat-1 cells. Analyses were done similarly as described for RIE-1 cells.
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(F2, Y806F/Y813F), triple (F3, Y784F/Y806F/Y813F), quadru-
ple (F4, Y770F/Y784F/Y806F/Y813F), and quintuple (F5,
Y770F/Y780F/Y784F/Y806F/Y813F) mutants. We then estab-
lishedmass populations of Rat-1 cells that stably expressedwild
type and mutant FGFR2 IIIb C1 proteins and compared their
transforming potency in soft agar assays.
We found that the Y770F mutation alone promoted colony
formation in soft agar (600 colonies per dish), whereas recep-
tors with the Y780F, Y784F, Y806F, or Y813F mutations
showed the same weak colony forming activity (200 colonies
per dish) as cells expressing the WT FGFR2 IIIb C1 receptor
(Fig. 2,A and B). In addition, we found that the F2 double or F3
triplemutant receptors showed the same transforming potency
as WT FGFR2 IIIb C1 (Fig. 2B), whereas the F4 quadruple and
F5 quintuple mutants that included the Y770F mutation pro-
moted colony formation in soft agar to the same extent as the
Y770F singlemutant (Fig. 2B).We found that all FGFR2 IIIb C1
mutants were expressed at a similar level asWT FGFR2 IIIb C1
(Fig. 2C), indicating that the differences in transforming activity
were not because of differences in steady-state levels of protein
expression.
Because the anti-FGFR2 antibody recognizes a carboxyl-ter-
minal epitope that is deleted inC2 andC3,we could not exclude
the possibility that different transforming potency of the C2
and C3 mutants may be due, in part, to different levels of
expression. As an indirect evaluation of receptor expression, we
did find that FGF7 stimulation of the cells expressing the C1,
C2, and C3 variants showed comparable levels of phosphoryla-
ted FRS2 (Fig. 7A), suggesting that the three isoforms were
expressed at comparable levels. Together, these results indicate
that loss of the Tyr-770 residue, but not other tyrosine residues
(Tyr-780, Tyr-784, Tyr-806, and Tyr-813), contributes to the
increased transforming potency of the C3 variant. However,
because the C2 variant retains Tyr-770 (Fig. 1A), the loss of this
residue is not the basis for the increased transforming activity of
the C2 variant.
It is notable that the C2 variant lacks 34 carboxyl-terminal
residues found in the C1 variant, but additionally, it is also
divergent from theC1 variant for three amino acids at positions
779, 783, and 787 (Fig. 1A). Although C1 contains 779Q/783S/
787T, C2 contains 779P/783C/787P. Therefore, we speculated
that differences in these three amino acids might contribute to
the increased transforming potency of the C2 variant. To
address this possibility, we generated a truncationmutant of C1
that has same length as C2 but contains the 779Q/783S/787T
sequence (designated C2 (QST)) rather than the 779P/783C/
787P sequence.We found that this C2 (QST) mutant exhibited
a similar transforming potency as the C2 variant (Fig. 2B), indi-
cating that the loss of the carboxyl-terminal 34 amino acids
(from 789 residue to 822 residue), and not differences in 779,
783, and 787 residues, is responsible for increased transforming
potency of the C2 variant.
Mutation of Y770F Does Not Activate FGFR2 IIIb C1 Trans-
forming Activity in RIE-1 Epithelial Cells—In contrast to our
observations in Rat-1 cells, Moffa and Ethier (32) showed that
mutation ofTyr-770 alonewas not sufficient to enhance FGFR2
IIIb C1 growth transforming activity when assayed in HME
mammary epithelial cells. One possible explanation for their
different conclusion is that fibroblasts, but not epithelial cells,
express the ligand (KGF/FGF7) for FGFR2 IIIb (11, 13, 16).
Therefore, FGFR2 IIIb can be activated in fibroblasts but not
epithelial cells by formation of an autocrine signaling loop (11,
13, 33, 34). Thus, we examined whether the Y770F mutation
enhanced FGFR2 IIIb C1 transforming activity when expressed
in RIE-1 epithelial cells. Consistent with the previous report
(32), we found that the Y770Fmutation did not increase FGFR2
FIGURE 2. Mutation of Y770F alone activates FGFR2 IIIb C1 transforming
activity in Rat-1 fibroblasts. A, Rat-1 cells that stably expressed the indi-
cated FGFR2 IIIb proteins were assayed for their ability to grow in soft agar.
Cells were suspended in 0.4% soft agar and photographed 21 days after plat-
ing. The C2(QST) indicates a truncation mutant of C1 that has same length as
C2 but contains the 779Q/783S/787T sequence. B, number of colonies was
quantitated after 21 days. Data shown are the average of duplicate dishes,
with the bars indicating standard deviation, and are representative of two
independent experiments. C, Rat-1 cells that stably express the indicated
FGFR2 IIIb proteins were assayed for their FGFR2 IIIb protein expression levels
by immunoblot analyses with FGFR2 antibody against a peptide sequence in
the FGFR2 IIIb C1 carboxyl-terminal sequence. This sequence has been
deleted in the FGFR2 IIIb C2 and FGFR2 IIIb C3 variants; therefore, we cannot
determine the level of expression of these two isoforms with this antibody.
Blot analysis with anti--actin was done to verify equivalent total protein
loading.
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IIIb focus forming activity in RIE-1 epithelial cells (Fig. 3A). To
exclude the possibility that different expression levels of pro-
teins contributed to different transforming activities, we deter-
mined all FGFR2 IIIb C1 mutants were expressed at a similar
level as WT FGFR2 IIIb C1 (Fig. 3B).
Breast carcinoma cells expressing FGFR2 IIIb in situ will be
exposed to FGFR2 IIIb ligands secreted by adjacent mesenchy-
mal stromal tissue (16). Therefore, we determined whether the
ligands secreted by fibroblasts can enhance the transforming
potency of the Y770F mutant when expressed in RIE-1 epithe-
lial cells. To address this question, conditioned medium from
Rat-1 fibroblast was collected and added to RIE-1 cells stably
expressing the WT or Y770F mutant receptor. Although Rat-1
fibroblast conditioned medium did not enhance the focus
forming activity of empty vector control and WT receptor-ex-
pressing cells, it promoted the focus forming activity of the
Y770F mutant (Fig. 3C). These observations suggest that both
loss of Tyr-770 and paracrine stimulation by fibroblast-ex-
pressed ligands are required for the enhanced transforming
activity of the Y770F mutant receptor in RIE-1 epithelial cells.
These results also provide a mechanistic explanation for the
negative observations of Moffa and Ethier (32) in mammary
epithelial cells.
To emphasize the importance of epithelial (FGFR2 IIIb)-
stromal (FGF7) interactions, for the remaining studies we used
Rat-1 fibroblasts as our model cell system. This allowed us the
ability to study how FGFR2 IIIb may function in epithelial cells
when exposed to FGFR2 IIIb ligands expressed by surrounding
stromal fibroblasts. Additionally, because Rat-1 cells do not
express endogenous FGFR2 IIIb receptors, our analyses of
mutant receptor function were not complicated by any activity
contributed by endogenous receptor activity.
Leu-773 but Not Tyr-770 of the 770YXXLMotif Is Required for
Ligand-induced FGFR2 IIIb C1 Internalization and
Degradation—Next, we sought to determine how mutation of
the Tyr-770 residue enhanced FGFR2 IIIb C3 transforming
activity. Interestingly, the Tyr-770 residue and flanking
sequences (770YLDL) correspond to a putative YXX motif
(  bulky hydrophobic residue) that is known to be themajor
determinant for endocytosis of many transmembrane proteins
(29). However, a previous study found that a Y770F mutation
did not impair FGFR2 IIIb internalization, arguing against this
possibility (23). Because there is evidence that the tyrosine res-
idue of the YXX sorting motif can be substituted with aro-
matic amino acids such as phenylalanine or tryptophan (35–
37), we postulated that if Tyr-770 is substituted with an alanine
instead of phenylalanine, the YXX sorting signal might be
disrupted. Alternatively, it is also possible that both theTyr-770
and Leu-773 residues of 770YXXL motif might be required for
FGFR2 internalization and that concurrent mutation of both
residues will be required to disrupt its function.
To determine whether the Tyr-770 and/or Leu-773 residues
are required for FGFR2 IIIb C1 internalization, we generated
mutant cDNA sequences encoding four FGFR2 IIIb C1 mis-
sense mutants (Y770F, Y770F/L773A, Y770A/L773A, and
L773A). Because steady-state protein levels may not reflect the
kinetics of receptor internalization and turnover, we compared
the ability ofWTandmutant receptors to undergo ligand-stim-
ulated internalization. For these analyses, Rat-1 cells that stably
expressed WT or mutant FGFR2 IIIb C1 proteins were stimu-
lated with either vehicle (BSA) or 50 ng/ml FGF7 and immuno-
stained with anti-FGFR2 antibody to determine the subcellular
localization of receptors. In unstimulated cells, the WT and all
four mutant receptors were found associated with the plasma
membrane aswell as in the intracellular compartment (Fig. 4A).
After FGF7 stimulation, no plasma membrane-associated WT
receptor was seen, with the majority internalized to punctate
vesicular structures (Fig. 4A). Similar to the WT receptor, the
FIGURE 3. Mutation of Y770F does not activate FGFR2 IIIb C1 transform-
ing activity in RIE-1 epithelial cells. A, RIE-1 cells that stably expressed the
indicated FGFR2 IIIb proteins were assayed for their ability to grow in soft
agar. The number of colonies was quantitated after 21 days. Data shown are
the average of duplicate dishes, with the bars indicating standard deviation,
and are representative of two independent experiments. B, RIE-1 cells that
stably express the indicated FGFR2 IIIb proteins were assayed for their FGFR2
IIIb protein expression levels by immunoblot analyses with anti-FGFR2 anti-
body that recognizes a peptide sequence in the FGFR2 IIIb C1, but not C2 or
C3, carboxyl-terminal sequence. C, mutation of Tyr-770 causes ligand-
dependent transformation of RIE-1 cells. RIE-1 cells stably infected with the
empty vector or encoding WT or Y770F mutant FGFR2 IIIb C1 were grown in
the regular growth medium or Rat-1 fibroblasts conditioned medium for 3
weeks (replenished every 2 days) before cells were fixed and stained with
crystal violet.
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majority of the Y770F mutant
receptor was also translocated to a
punctate vesicular structure after
FGF7 stimulation. However, all
three mutant receptors containing
the L773A substitution (Y770F/
L773A, Y770A/L773A, and L773A)
showed impaired ability to internal-
ize and retain significant plasma
membrane association after FGF7
stimulation (Fig. 4A).
To quantitatively determine
FGFR2 IIIb internalization, we
labeled cell surface FGFR2 IIIb with
a cleavable biotin, and then meas-
ured the extent of translocation of
the biotinylated FGFR2 IIIb to intra-
cellular compartments. Consistent
with immunostaining analyses, we
found that the Y770F mutation did
not impair receptor internalization,
whereas all three mutant receptors
containing the L773A substitution
(Y770F/L773A, Y770A/L773A, and
L773A) caused 50% inhibition of
internalization when compared
with the WT and Y770F mutant
receptors (Fig. 4B). Together, these
data indicate that the Leu-773 but
not Tyr-770 residue is critical for
FGFR2 IIIb C1 internalization. In
general, after ligand-stimulated
internalization, receptors translo-
cate to the lysosomal compartment
and are degraded (29). Thus, we
next determined the role of Tyr-770
and Leu-773 residues in ligand-in-
duced receptor degradation. For
these analyses, Rat-1 cells that sta-
bly express WT or YXXL mutant
receptors were stimulated with
FGF7, and the amount of total
FGFR2 IIIb protein remaining was
monitored for 0–6 h (Fig. 4C).
FGF7 stimulation caused a signifi-
cant decrease in both WT and
Y770F mutant receptors (70%
decrease in receptor protein com-
pared with the untreated control
cells after 4 h of FGF7 stimulation).
In contrast, the three mutant recep-
tors containing the L773A substitu-
tion (Y770F/L773A, Y770A/L773A,
and L773A) exhibited a decreased
rate of FGF7-induced degradation
(30% decrease in receptor protein
compared with the untreated con-
trol cells after 4 h of FGF7 stimula-
FIGURE 4. Mutation of the Leu-773 but not Tyr-770 residue of the 770YXXL motif causes impaired ligand-
induced FGFR2 IIIb C1 internalization and degradation and sustained activation of FGFR2 IIIb. A, mutation of
the Leu-773 residue of the 770YXXL motif reduces ligand-stimulated FGFR2 IIIb C1 dissociation from the plasma
membrane. Rat-1 cells that stably express the indicated FGFR2 IIIb proteins were serum-starved for 20 h and then
incubated with serum-free medium supplemented with either vehicle (BSA) or 50 ng/ml FGF7 for 40 min at 37 °C.
The cells were fixed, permeabilized, and immunostained with anti-FGFR2 antibody to determine FGFR2 IIIb subcel-
lular location by confocal microscopy. B, mutation of the Leu-773 residue of the 770YXXL motif reduces FGFR2 IIIb C1
internalization. Following surface biotinylation with thiol-cleavable sulfo-NHS-S-S-biotin, cells were treated with
FGF7 (50 ng/ml) for the indicated time intervals to allow internalization of biotinylated FGFR2 IIIb and processed as
described under “Experimental Procedures.” The amount of internalized receptor was determined by immunoblot-
ting with FGFR2 antibody (left panel) and quantified as a percentage of the amount of total surface labeling (Total)
that was measured in the absence of a biotin cleavage step (right panel). Data shown are the average of two inde-
pendent experiments with the bars indicating standard deviation. C, mutation of Leu-773 of the 770YXXL motif
reduces the rate of ligand-induced FGFR2 IIIb C1 degradation. Rat-1 cells that stably express either wild type or
mutant FGFR2 IIIb proteins were incubated with 50 ng/ml FGF7 for the indicated times at 37 °C to induce ligand-
induced receptor degradation. Immunoblotting analyses with FGFR2 antibody were performed to determine the
level of remained FGFR2 protein (left panel). The receptor remaining indicates the percentage of FGFR2 IIIb remaining
in FGF7-stimulated cells when compared with untreated control cells (right panel). The data shown are the average
of two independent experiments with the bars indicating standard deviation. D, loss of the Leu but not Tyr residue
of the 770YXXL motif causes sustained activation of FGFR2 IIIb. Rat-1 cells stably expressing the indicated FGFR2 IIIb
proteins were stimulated with either vehicle or 50 ng/ml FGF7 for 20 min. To determine FGFR2 autophosphoryla-
tion, cells were lysed and immunoprecipitated (IP) with anti-FGFR2 antibody followed by immunoblotting (IB) with
anti-phosphotyrosine (P-Tyr) antibody.
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tion). These data indicate that the Leu-773 but not Tyr-770
residue is critical for ligand-induced FGFR2 IIIb C1
degradation.
Loss of the Leu but Not Tyr Residue of the 770YXXL Motif
Causes Sustained Activation of FGFR2 IIIb—To determine
whether the impairments in receptor internalization and deg-
radation were correlated with aberrant activation of FGFR2
IIIb, Rat-1 cells that stably express WT or mutant receptors
(Y770F, Y770F/L773A, Y770A/L773A and L773A) were stimu-
lated with either vehicle or FGF7 for 20 min. Then cells were
lysed and immunoprecipitated with FGFR2 antibody followed
by immunoblot analyses with phosphotyrosine antibody to
detect FGFR2 IIIb autophosphorylation.
FGF7 stimulation caused comparable increased tyrosine
phosphorylation of the WT and all four mutant receptors (Fig.
4D). In the absence of FGF7, both the WT and Y770F mutant
receptors showed low levels of tyrosine phosphorylation. In
contrast, all three internalization defective mutants lacking the
Leu-773 residue (Y770F/L773A, Y770A/L773A, and L773A)
showed significantly higher levels of tyrosine-phosphorylated
FGFR2 IIIb when compared with the WT and Y770F mutant
receptors (Fig. 4D). Taken together, these data suggest that loss
of the Leu-773 residue results in sustained activation of FGFR2
IIIb that may be caused by decreased receptor internalization
and degradation.
Loss of the Tyr and Leu Residues of the 770YXXL Motif
Enhances FGFR2 IIIb Transforming Activity by Distinct
Mechanisms—We next determined whether loss of the Leu-
773 residue, to cause impaired receptor down-regulation and
sustained FGFR2 IIIb activation (Fig. 4), was also associated
with an enhanced FGFR2 IIIb C1 transforming activity. We
found that the L773Amutation alone was sufficient to enhance
the anchorage-independent growth potential of FGFR2 IIIb
(Fig. 5A). Because the Y770F mutation did not impair receptor
down-regulation and did not induce sustained FGFR2 IIIb acti-
vation (Fig. 4), yet was associated with enhanced FGFR2 IIIb
transforming activity (Fig. 2), the Y770F and L773A mutations
appear to cause distinct consequences on receptor function
that promote transformation. If so, we would expect that the
concurrent mutation of the Tyr-770 and Leu-773 residues
should cause synergistic enhancement of FGFR2 IIIb trans-
forming activity of FGFR2 IIIb C1. As expected, we found that
both the Y770F/L773A and Y770A/L773A double mutants
(10-fold more soft agar colonies thanWT) exhibited 2-fold
higher transforming activity when compared with either the
Y770F (6-fold more soft agar colonies than WT) or L773A
(4-fold more soft agar colonies thanWT) single mutant (Fig.
5A). To exclude the possibility that different expression level of
proteins could have an effect on transforming potency, we
determined all FGFR2 IIIb proteins tested above were
expressed at comparable levels (Fig. 5B). Taken together, these
data indicate that concurrent loss of theTyr and Leu residues of
the 770YXXL motif cooperates to enhance the transforming
activity of the FGFR2 IIIb C3 isoform.
Loss of Tyr-770 Impairs FGFR2 IIIb C1 Activation of PLC—
Although the Y770F mutation did not impair receptor down-
regulation (Fig. 4), the Y770F mutation did enhance the trans-
forming activity of FGFR2 IIIb (Fig. 5A). These observations
suggest that some other mechanism(s) contributes to the
enhanced transforming activity of the Y770F mutant. A recent
study showed that a Y770F missense mutant of FGFR2 IIIb C1
cannot bind and phosphorylate PLC (23). However, in con-
trast to our observations, this study found that the Y770Fmuta-
tion impaired, rather than enhanced, ligand-stimulated mito-
genic activity (23).
To resolve these apparently conflicting observations, we
decided to more thoroughly evaluate the role of Tyr-770 in
FGFR2 IIIb regulation of PLC signaling and transforming
activity. First, we determinedwhethermutation of Tyr-770 and
other 770YXXL motif residues caused decreased tyrosine phos-
phorylation of PLC. For these analyses, Rat-1 cells stably
expressing WT and mutant FGFR2 IIIb C1 (Y770F, Y770F/
L773A, Y770A/L773A, and L773A), as well as the C2 and C3
variants, were stimulated with FGF7, and the level of PLC
tyrosine phosphorylationwas determined. As expected theWT
FIGURE 5. Mutation of the Tyr and Leu residues of the 770YXXL motif coop-
erates to enhance FGFR2 IIIb C1 induction of anchorage-independent
growth transformation. A, FGFR2 IIIb C1 770YXXL motif mutants exhibit
enhanced colony formation in soft agar. Rat-1 cells that stably express the
indicated FGFR2 IIIb proteins were suspended in 0.4% soft agar and allowed
to grow for 14 days before the number of colonies was quantitated. Data
shown are the average of duplicate dishes, with the bars indicating standard
deviation, and are representative of three independent experiments. B, wild
type and 770YXXL motif mutants of FGFR2 IIIb C1 are stably expressed at com-
parable levels. Rat-1 cells that stably expressed the indicated FGFR2 IIIb pro-
teins were assayed for their FGFR2 IIIb protein expression levels by immuno-
blot analyses with anti-FGFR2 antibody. Total cell lysates were also blotted
with anti--actin to verify equivalent total protein.
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FGFR2 IIIb C1 and C2 variants that contain Tyr-770, and not
the C3 that lacks Tyr-770, showed increased FGF7-stimulated
levels of tyrosine-phosphorylated PLC (Fig. 6A). Moreover,
we found that all three FGFR2 IIIb C1 mutants that lack the
Tyr-770 residue (Y770F, Y770F/L773A, and Y770A/L773A)
failed to exhibit elevated tyrosine-phosphorylated PLC,
whereas the L773A mutant retained the ability to stimulate
tyrosine phosphorylation of PLC (Fig. 6A). Finally, whether
the Tyr-770 residue is required for PI hydrolysis was not deter-
mined by the previous study (23). We found that FGF7 stimu-
lation inducedmarked [3H]inositol phosphate response in cells
stably expressing the wild type and not Y770F mutant FGFR2
IIIb C1 receptor (Fig. 6B). Taken together, these data suggest
that Tyr-770 is required for activation of PLC by FGFR2 IIIb,
and the loss of capacity to promote inositol lipid hydrolysis
might contribute to the enhanced transforming activity of the
C3 variant that lacks Tyr-770.
Loss of Tyr-770 Causes Sustained Activation of FRS2 but Not
Ras-MAPK or PI3K-AKTPathways—PLC-mediated signaling
is generally considered to promote mitogenesis and growth
(38–40). Thus, the fact that the Y770F mutation enhances
FGFR2 IIIb C1 transforming activ-
ity, yet results in the loss of PLC
activation, argues that mutation of
Tyr-770 may affect other signaling
activities that promote growth
transformation. One possible expla-
nation for this paradoxical observa-
tion is that loss of PLC binding
caused by the Y770F mutation may
indirectly promote the activation of
other FGFR2 IIIb effector pathways.
Aside fromPLC, the FRS2 proteins
represent the next best character-
ized effectors of FGFR signaling
(1–4).
To determine whether loss of
Tyr-770 altered FRS2 activity, Rat-1
cells stably expressing WT or
mutants of FGFR2 IIIb C1 as well as
the C2 and C3 variants were lysed
and immunoprecipitated with anti-
FRS2 antibody followed by immu-
noblot analyses using anti-phos-
photyrosine antibody. We found
that mutant receptors with the Tyr-
770 mutation (Y770F, Y770F/
L773A, and Y770A/L773A) showed
elevated basal FRS2 tyrosine phos-
phorylation in the absence of exog-
enous FGF7 stimulation (Fig. 7A).
Consistent with these observations,
elevated basal FRS2 tyrosine phos-
phorylation was also seen for the C3
isoform that lacks Tyr-770 but not
the C2 isoform that retains Tyr-770
(Fig. 7A). The sustained activation
of FRS2 observed in the absence of
FGF7 seemed likely to be caused by receptor stimulation by
endogenous ligands secreted by Rat-1 fibroblasts. After
stimulation with FGF7 for 20 min, all three FGFR2 IIIb splice
variants as well as the mutants of C1 showed increased levels
of robustly tyrosine-phosphorylated FRS2 (Fig. 7A), indicat-
ing that all the receptor variants retained efficient coupling
to FRS2.
Because we observed sustained FRS2 activation in Tyr-770
mutants in the absence FGF7 stimulation (Fig. 7A), we next
determined whether this was associated with sustained activa-
tion of FRS2-mediated downstream signaling pathways acti-
vated transiently by ligand stimulation. We first examined
whether loss of Tyr-770 led to activation of Ras and the Raf-
MEK-ERK MAPK pathway. For these analyses, we utilized
immunoblot analyses with a phospho-specific MEK1/2 or
phospho-specific ERK1/2 antibodies. After stimulation with
FGF7 for 20 min, MEK was phosphorylated in WT and all
mutants to a similar extent. Similarly, FGF7 stimulation
caused robust phosphorylation of ERK in WT and all
mutants to a similar extent. In the absence of FGF7, surpris-
ingly, none of the FGFR2 IIIb proteins tested above caused
FIGURE 6. Loss of Tyr-770 but not Leu-773 impairs FGFR2 IIIb C1 activation of PLC. A, mutation of Tyr-770
but not Leu-773 impairs phosphorylation of endogenous PLC. Rat-1 cells stably expressing indicated FGFR2
IIIb proteins were serum-starved and stimulated with either vehicle or 50 ng/ml FGF7 for 30 min. Tyrosine-
phosphorylated and total PLC protein was determined by immunoprecipitation (IP) with anti-PLC antibody
followed by immunoblotting (IB) with anti-phosphotyrosine (P-Tyr) antibody or with anti-PLC antibody,
respectively. Data shown are representative of three independent experiments. B, mutation of Tyr-770 impairs
FGF7-stimulated formation of inositol phosphates. Rat-1 cells stably expressing the indicated wild type (WT)
or mutant FGFR2 IIIb C1 proteins were serum-starved and stimulated with vehicle (basal), or with 100
ng/ml FGF7, 0.1 M thrombin, or 10 M lysophosphatidic acid (LPA) (positive controls), and [3H]inositol
phosphate accumulation was measured to assess PLC activity. Data shown are representative of three
independent assays.
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an increase in the steady-state levels of activated MEK or
ERK (Fig. 7B).
Next, we determined whether mutation of Tyr-770 led to
sustained activation Gab1 and the PI3K-AKT pathway. For
these analyses, cells were lysed and immunoprecipitated with
Gab1 antibody followed by immunoblot analyses with phos-
photyrosine antibody to determine Gab1 activity. In addition,
we utilized immunoblot analyses with a phospho-specific anti-
body that recognizes the phosphorylated and activated forms of
AKT to determine AKT activity. FGF7 stimulation for 20 min
caused Gab1 phosphorylation in WT and all mutants to a sim-
ilar extent. FGF7 stimulation also induced a similar level of
AKT phosphorylation in WT and mutant receptors. However,
in the absence of FGF7 stimulation, no increased steady-state
activation of Gab1 or AKT was detected for cells expressing
WT or mutant receptors (Fig. 7B). These data suggest that
whereas loss of Tyr-770 caused sustained FRS2 activation, it did
not induce sustained activation of the ERK or Gab1-PI3K-AKT
pathways.
Although we found that loss of Tyr-770 did not cause an
increase in steady-state activation of theRas-ERKor PI3K-AKT
signaling pathways, it is possible that both pathways are still
persistently activated but down-regulated by feedback mecha-
nisms present during persistent signaling. Thus, we determined
whether the activities of these two pathways were still impor-
tant for Y770F transforming activity. We found that treatment
with either the U0126 MEK inhibitor or the LY294002 PI3K
inhibitor inhibited the anchorage-independent growth of cells
expressing Y770F (Fig. 7C), indicating that bothMEK-ERK and
PI3K activities contribute to the enhanced transforming activ-
ity caused by the Y770F mutation.
Loss of Tyr-770 Enhances FRS2 Binding to FGFR2—Next, we
decided to determine how loss of the PLC-binding site (Tyr-
770) leads to sustained tyrosine phosphorylation of FRS2. One
possible explanation for these observations is that PLC bind-
ing to FGFR2 may interfere with complex formation between
FRS2 and FGFR2. By abolishing PLC binding, the Y770F
mutation might relieve steric hindrance for FRS2 and facilitate
its binding to the FGFR2. Consequently, loss of PLC binding
by the Y770F mutation may indirectly enhance FRS2 activity.
To examine this possibility, we determined whether the loss of
the PLC-binding site (Tyr-770) enhances FRS2 association
with the FGFR2. For these analyses, Rat-1 cells stably express-
ing WT or mutants of FGFR2 IIIb C1 (Y770F, Y770F/L773A,
Y770A/L773A, and L773A) were lysed and immunoprecipi-
tated with anti-FRS2 antibody followed by immunoblot analy-
ses using anti-FGFR2 antibody. Previously, Ong et al. (24)
reported that FGFR1 interacts with FRS2 constitutively, inde-
pendent of receptor activation. Consistent with this study, we
also found that FRS2 constitutively associated with the wild
type and all mutants of FGFR2 examined. However, we
observed 1.7-fold increase of FRS2 binding to FGFR2 in
mutants lacking Tyr-770 (Y770F, Y770F/L773A, Y770A/
L773A) when comparedwith theWTor L773Amutant (Fig. 8).
These data indicate that loss of Tyr-770 but not Leu-773
enhances FRS2 association with FGFR2, and this enhanced
FRS2 association with FGFR2 may lead to sustained receptor
activation of FRS2.
FRS2 Binding Is Required for Increased FRS2 Tyrosine Phos-
phorylation and Enhanced Transforming Activity by the Y770F
Mutation—Next, we determined whether FRS2 binding is
required for the increased tyrosine phosphorylation and trans-
forming activity caused by the Y770F mutation. For these anal-
yses, we generated mutants of FGFR2 IIIb C1 that cannot bind
FRS2. Previously, it was demonstrated that FRS2 binds consti-
FIGURE 7. Loss of the Tyr-770 causes sustained steady-state activation of
FRS2 but not MEK-ERK or Gab1-AKT pathways. A, loss of Tyr-770 causes
sustained activation of FRS2 in the absence of FGF7 stimulation. Rat-1 cells
stably expressing the indicated FGFR2 IIIb proteins were grown to confluence
and stimulated with either vehicle or 50 ng/ml FGF7 for 20 min. Then cells
were lysed, and FRS2 activity was determined by immunoprecipitation (IP)
with anti-FRS2 antibody followed by immunoblotting (IB) with anti-phospho-
tyrosine (P-Tyr) antibody. Total cell lysates were analyzed to determine stable
FGFR2 IIIb protein expression levels by immunoblot analyses with anti-FGFR2
antibody. B, Rat-1 cells stably expressing the indicated FGFR2 IIIb proteins
were stimulated with either vehicle or 50 ng/ml FGF7 for 20 min. MEK, ERK, or
AKT activation was determined by immunoblot analyses using antibody that
recognizes activated, phosphorylated forms of MEK, ERK, or AKT, respectively.
To determine Gab1 activity, cells were lysed and immunoprecipitated with
anti-Gab1 antibody followed by immunoblot analysis with phosphotyrosine
antibody. C, MEK and PI3K activities are required for enhanced transforming
potency by Y770F mutation. Rat-1 cells stably expressing the indicated FGFR2
IIIb were suspended in 0.4% soft agar. The cells were incubated for 3 weeks in
the absence or presence of 10 M LY294002 (PI3K inhibitor) or 30 M U0126
(MEK inhibitor). Cells were photographed about 3 weeks after plating. Colo-
nies per dish were counted 3 weeks after plating. Data shown are the average
of duplicate dishes, with the bars indicating standard deviation, and are rep-
resentative of two independent experiments.
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tutively to the juxtamembrane region of FGFR1 (24). They also
determined thatmutation of the Lys-419, Pro-422, andLeu-423
residues in the juxtamembrane region strongly diminished
interaction between FGFR1 and the FRS2 (24). Because the Lys-
419, Pro-422, and Leu-423 residues in the juxtamembrane
region of FGFR1 are well conserved in FGFR2 IIIb, to generate
a FRS2-binding deficient mutant, we constructed a mutant of
FGFR2 IIIb (K421A/P424A/L425A, designated FRS2) that is
analogous to the FGFR1 mutant (K419A/P422A/L423A).
Todeterminewhether FRS2binding is required for sustained
activation of FRS2 by Y770F mutation, we introduced muta-
tions in the FRS2 binding region (FRS2) in the Tyr-770
mutant (designated as Y770F/FRS2). Rat-1 cells stably
expressingWT, Y770F, or Y770F/FRS2were lysed and immu-
noprecipitatedwith anti-FRS2 antibody and followed by immu-
noblot analyses using anti-phosphotyrosine antibody. Consist-
ent with our observation in Fig. 7A, we found that the Y770F
mutation enhanced FRS2 tyrosine phosphorylation in the
absence of FGF7 stimulation, and this activation was abolished
by the loss of FRS2 binding (Fig. 9A). These observations indi-
cate that FRS2 binding to FGFR2 is essential for sustained acti-
vation of FRS2 by the Y770F mutant receptor.
FIGURE 8. Loss of Tyr-770 enhances FRS2 binding to FGFR2. A, Rat-1 cells
stably expressing the indicated FGFR2 IIIb proteins were lysed and FRS2-
FGFR2 binding was determined by immunoprecipitation (IP) with anti-FRS2
antibody followed by immunoblotting (IB) with anti-FGFR2 antibody. To
determine total endogenous FRS2 protein, the same membrane was rep-
robed with anti-FRS2 antibody. Total cell lysates were analyzed to determine
stable FGFR2 IIIb protein expression levels by immunoblot analyses with anti-
FGFR2 antibody. Data shown are representative of three independent exper-
iments. B, quantitation of data shown in A. FGFR2-FRS2 binding indicates the
relative band intensity of mutant FGFR2 bound to FRS2 when compared with
the wild type FGFR2 bound to FRS2. Data shown represent as the average of
three independent experiments with the bars indicating standard deviation.
FIGURE 9. FRS2 binding to FGFR2 is required for increased FRS2 tyrosine
phosphorylation and enhanced transforming activity by the Y770F
mutation. A, FRS2 binding is required for enhanced FRS2 tyrosine phospho-
rylation by Y770F mutation. Rat-1 cells stably expressing the indicated pro-
teins were analyzed for FRS2 activity by immunoprecipitation (IP) with either
anti-FRS2 antibody or anti-phosphotyrosine antibody followed by immuno-
blotting (IB) with either anti-phosphotyrosine or anti-FRS2 antibody, respec-
tively. Total cell lysates were analyzed by immunoblot analyses with anti-
FGFR2 antibody to verify equivalent expression of the C1 variants. FRS2
corresponds to the K421A/P424A/L425A mutations in the FRS2-binding site.
B, FRS2 binding is required for increased FGFR2 IIIb C1 transforming activity
by the Y770F mutation. Rat-1 cells stably expressing the indicated FGFR2 IIIb
proteins were suspended in 0.4% soft agar and allowed to grow for about 21
days before the number of colonies was quantitated. Data shown are the
average of duplicate dishes, with the bars indicating standard deviation, and
are representative of three independent experiments.
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Finally, we determined whether loss of FRS2 binding and
activation was associated with a reduction in the transforming
activity of the Y770F mutant. When we introduced the FRS2
mutation into the Y770F mutant, the resulting Y770F/FRS2
mutant showed a similar weak transforming activity as seen
with WT C1 (Fig. 9B). This observation indicates that the
enhanced transforming potency caused by the Y770Fmutation
is dependent on FRS2 binding and activity.
DISCUSSION
Although missense mutations of FGFR2 are found in human
cancers (41), anothermechanismof FGFR2 activation in cancer
may involve alternative gene splicing and enhanced expression
of the structurally and functionally distinct C2 and C3 variant
receptors. In this study, we compared the transforming potency
of the C1, C2, and C3 splicing variants of FGFR2 IIIb and found
that progressive loss of carboxyl-terminal sequences is corre-
lated with increased transforming potency. Ourmutation anal-
yses of the 770YXXLmotif suggest that the absence of this motif
contributes to the highly transforming nature of the C3 splice
variant by decreased receptor internalization and increased
receptor expression activation and by enhanced activation of
FRS2 (Table 1 and Fig. 10). Thus, the preferential expression of
the C3 isoform in cancer cells represents another mechanism
for altered receptor signaling that contributes to oncogenesis.
In light of observations by us and others (18), it would seem
most logical to study the signaling and transforming function of
the epithelial cell-restricted FGFR2 IIIb splice variants in epi-
thelial cells. However, in situ tumor epithelial cells are associ-
ated with mesenchymal stromal tissue, which secrete ligands
that cause persistent paracrine stimulation of FGFR2 IIIb in
epithelial cells. Hence, we speculated that a more accurate
approach for evaluating FGFR2 IIIb function would be in fibro-
blast cells, where secreted fibroblast cell-derived ligands will
foster a persistent autocrine stimulation of FGFR2 IIIb. As dis-
cussed below, our observations found differences in FGFR2 IIIb
signaling and transforming activity when evaluated under con-
ditions of transient or sustained ligand stimulation in epithelial
and fibroblast cells, thus supporting the physiologic significa-
tion of our studies of FGFR2 IIIb function in fibroblasts with
regards to FGFR2 IIIb function in epithelial cell-derived tumors
in vivo.
We determined that loss of the Tyr-770 alone significantly
enhanced the transforming activity of FGFR2 IIIb C1. This
observation was unexpected because the Y770F residue is a
PLC-binding site, and PLC is generally considered as a
growth-promoting protein. Because this residue also corre-
sponds to a putative YXXL tyrosine-based sorting motif, we
evaluated the consequences of mutation of the 770YXXL motif
on receptor internalization. Surprisingly, we found that loss of
Leu-773 but not Tyr-770 residue impaired ligand-induced
receptor internalization and degradation. Interestingly, impair-
ment of receptor internalization was correlated with sustained
activation of FGFR2 IIIb.We also found that concurrent muta-
tion of the Tyr-770 and Leu-773 residues cooperatively
enhanced transforming activity. Furthermore, we found that
loss of the PLC-binding site (Tyr-770) caused sustained FRS2
activation by enhancing FRS2 association with FGFR2. Muta-
tion of the FRS2-binding site impaired FGFR2 IIIb transform-
ing activity, supporting a necessary role for FRS2 in FGFR2 IIIb
receptor activation by loss of the 770YXXL motif. These results
support a model where the enhanced transforming activity of
FGFR2 IIIb C3 is because of two distinctmechanisms caused by
the deletion of sequences that include the 770YXXL motif,
altered receptor trafficking and signaling (Fig. 10).
In contrast to our observations, a previous study found that a
Y770F mutation impaired, rather than promoted, ligand-stim-
ulated FGFR2 IIIIb C1-mediated cell proliferation (23). Their
results are more consistent with other observations, where
PLC activation has been generally considered to promote,
rather than antagonize, growth. For example, overexpression of
PLC was shown to promote growth transformation of NIH
3T3 mouse and rat 3Y1 fibroblasts (40, 42). In addition, the
analogous Y760F mutation in tumor-derived constitutively
activatedmutants of FGFR3 (the K650Emissense and the TEL-
FGFR3 fusion protein) was shown to abolish PLC activation
and inhibited their transforming activities in Ba/F3 mouse
TABLE 1




WT Y770F L773A Y770F/L773A
FGFR2 transforming activityb    
FGFR2 internalization ratec    
FGFR2 expression levelsc    
FGFR2 autophosphorylationb    
PLC phosphorylationb  	  	
FRS2 phosphorylationb    
FRS2-FGFR2 bindingb    
Phospho-MEK1/2b 	 	 	 	
Phospho-ERK1/2b 	 	 	 	
Gab1 phosphorylationb 	 	 	 	
Phospho-AKTb 	 	 	 	
a Data were compiled from this study.
b Data were determined at steady state.
c Data were transient and FGF7-stimulated.
FIGURE 10. Loss of the 770YXXL motif in FGFR2 IIIb C3 enhances transform-
ing activity by altered receptor recycling and signaling. Based on our
observations with missense mutations in the 770YXXL motif, we propose a
model where the absence of the 770YXXL motif contributes to the enhanced
transforming potency of FGFR2 IIIb C3. First, loss of the Leu-773 residue
causes impaired ligand-stimulated receptor internalization and degradation.
Impairment in receptor down-regulation may further induce sustained acti-
vation of FGFR2 IIIb. Second, loss of the Tyr-770 results in a loss of PLC bind-
ing, which may relieves steric hindrance for FRS2 association, facilitating
enhanced FGFR2 binding. The increased FRS2 binding to FGFR2 may lead to
increased FRS2 activity and enhance transformation. Together, our results
suggest a mechanism where loss of Tyr and Leu residues of 770YXXL motif
cooperates to increase FGFR2 C3-mediated transformation.
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pro-B cells (43). A similar conclusion was made for platelet-
derived growth factor receptor activation of PLC, where selec-
tive loss of PLC activation resulted in loss of transforming
activity (39). However, in contrast to these observations, it was
shown that the Y766F mutation in FGFR1 abolished ligand-
stimulated PLC activation but not mitogenesis, as measured
by DNA synthesis in L6 myoblasts (20, 44), suggesting that
PLC activity is not required for FGFR1-mediated growth stim-
ulation. These different conclusions for PLC regulation of cell
proliferation may reflect distinct functions of FGFR isoforms.
Additionally, they may reflect cell context variations in PLC
biological function as well as the different biological assays uti-
lized. Another possible explanation for these conflicting obser-
vations is that this tyrosine residue may regulate PLC-inde-
pendent functions that regulate cell growth. For example, it was
shown that the PLC-binding site on PDGFR can serve as a
binding site for ubiquitin ligase Cbl that negatively regulates
PDGFR signaling (45).
In contrast to our study, where we found that a Y770Fmuta-
tion caused sustained FRS2 tyrosine phosphorylation, Ceri-
dono et al. (23) found that this samemutation diminished FRS2
tyrosine phosphorylation. We speculate that our different
observations may reflect the different consequences of tran-
sient versus sustained ligand stimulation. In the previous study,
transient (10 min) exogenous FGF7 stimulation was evaluated,
whereas our analyses evaluated the consequences of sustained
stimulation of FGFR2 by endogenous ligands. In support of this
possibility, our evaluation of FGFR2 IIIb activation of FRS2 sig-
naling found differences in transient versus persistent ligand
stimulation. There is considerable evidence that the duration of
signaling can elicit different biological and signaling outcomes
(46–48). For example, although we found that transient exog-
enous FGF7 stimulation increased FRS2 tyrosine phosphoryla-
tion in WT and Y770F mutant receptors to a similar extent,
sustained endogenous ligand stimulation increased FRS2 tyro-
sine phosphorylation only in the Y770F mutant but not WT
receptor (Fig. 7A).
Although the Y770Fmutant receptor induced sustained acti-
vation of FRS2, and we showed that loss of FRS2 binding
impaired transformation, we were surprised to find that
increased FRS2 activation was not associated with increased
steady-state activation of the ERK or AKT signaling pathways
(Fig. 7B). However, this result is not entirely surprising because
FRS2 is also known to facilitate negative regulatory compo-
nents to dampen FGFR signaling (2, 49). For example, ligand
stimulation of FGFR1 results in ERK-mediated phosphoryla-
tion of FRS2 at threonine residues, leading to attenuation of
ERK activation (50). Ligand stimulation of FGFR normally
causes a rapid and transient activation of ERK, and prevention
of ERK phosphorylation of FRS2 results in prolonged ERK acti-
vation (50). Finally, our finding that pharmacologic inhibition of
MEK-ERKsignaling or PI3Kactivation also reducedY770F recep-
tor transforming activity suggests that these two FRS2 effector
pathways do contribute to transformation. Nevertheless, it
remains possible that FRS2-mediated growth transformationmay
involve other signaling activities that remain to be identified.
In summary, our studies identified amechanistic basis for the
potent transforming activity of the C3 isoform of FGFR2 IIIb
that involves two distinct mechanisms regulated by the
770YXXL motif. Although the Y770F/L773A mutant showed
significantly higher transforming activity when compared with
the WT receptor, the C3 variant was still more transforming
than the Y770F/L773A mutant. Thus, our future studies will
focus on defining additional mechanisms for the enhanced
transforming potency of the C3 variant. Although we found
that the C2 variant was more transforming than the C1 var-
iant, the loss of the 770YXXL motif does not appear to account
for C2 transforming activity, and therefore, we have not found a
clear mechanistic basis for the enhanced transforming potency
of the C2 variant. Finally, FRS2 possesses multiple tyrosine
phosphorylation sites and can interactwith other signaling pro-
teins that may contribute to ERK and AKT independent mech-
anisms that promote transformation. Thus, our future studies
will include the identification of the critical signaling proteins
important for FRS2-mediated growth transformation.
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